Dr. Ulrich Brinkmann is an Expert Scientist and Scientific Director at Roche Pharma Research & Early Development in Munich, where they focus on protein and antibody engineering, bispecifics, and targeted payload delivery. Prior to joining Roche in 2012, they held leadership roles as Chief Scientific Officer at Xantos Biomedicine and Epidauros Biotechnology, contributing significantly to functional genomics, pharmacogenetics, and cancer therapy innovations. Dr. Brinkmann's earlier work at the National Cancer Institute involved developing recombinant antibodies and immunotoxins, which advanced to clinical trials. They earned a PhD in Molecular Biology from Boehringer Mannheim Research Laboratories and Stuttgart University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices